NDAINJECTIONINJECTABLE
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AMIODARONE HYDROCHLORIDE (amiodarone hydrochloride) by Medica Corp is drug, but it possesses electrophysiologic characteristics of all four vaughan williams classes. First approved in 2004.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Amiodarone hydrochloride is a multi-class antiarrhythmic agent that blocks sodium, potassium, and calcium channels while exerting antisympathetic effects, making it effective for treating life-threatening cardiac arrhythmias. It is administered intravenously and works by prolonging the cardiac action potential and refractory period across all cardiac tissues. The drug is indicated for patients with severe ventricular and supraventricular arrhythmias who are refractory to other therapies.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting limited growth opportunities and potential team consolidation.
Mechanism of Action
drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with…
Worked on AMIODARONE HYDROCHLORIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.